Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. Nijhof IS, et al. Among authors: van velzen j, van de donk nw, van duin m, van kessel b. Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15. Blood. 2016. PMID: 27307294 Free article. Clinical Trial.
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P; Dutch-Belgian HOVON group; German GMMG Group. Broyl A, et al. Among authors: van duin m, van der holt b. Blood. 2013 Jan 24;121(4):624-7. doi: 10.1182/blood-2012-06-438101. Epub 2012 Dec 11. Blood. 2013. PMID: 23233657 Free article. Clinical Trial.
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: van de donk nwcj, van duin m. Blood Adv. 2021 Apr 27;5(8):2196-2215. doi: 10.1182/bloodadvances.2020003805. Blood Adv. 2021. PMID: 33890981 Free PMC article.
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P. Kuiper R, et al. Among authors: van vliet mh, van duin m, van der holt b, van beers eh. Blood. 2015 Oct 22;126(17):1996-2004. doi: 10.1182/blood-2015-05-644039. Epub 2015 Sep 1. Blood. 2015. PMID: 26330243 Free PMC article.
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.
Kuiper R, Zweegman S, van Duin M, van Vliet MH, van Beers EH, Dumee B, Vermeulen M, Koenders J, van der Holt B, Visser-Wisselaar H, Hansson M, van der Velden AWG, Beverloo HB, Stevens-Kroef M, Levin MD, Broijl A, Waage A, Sonneveld P. Kuiper R, et al. Among authors: van vliet mh, van der velden awg, van duin m, van der holt b, van beers eh. Blood Adv. 2020 Dec 22;4(24):6298-6309. doi: 10.1182/bloodadvances.2020002838. Blood Adv. 2020. PMID: 33351127 Free PMC article. Clinical Trial.
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P. Broyl A, et al. Among authors: van duin m, van der holt b. Blood. 2010 Oct 7;116(14):2543-53. doi: 10.1182/blood-2009-12-261032. Epub 2010 Jun 23. Blood. 2010. PMID: 20574050 Free article.
A gene expression signature for high-risk multiple myeloma.
Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P. Kuiper R, et al. Among authors: van vliet mh, van duin m, van der holt b, van beers eh. Leukemia. 2012 Nov;26(11):2406-13. doi: 10.1038/leu.2012.127. Epub 2012 May 8. Leukemia. 2012. PMID: 22722715
Multiple myeloma.
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Kumar SK, et al. Among authors: van duin m. Nat Rev Dis Primers. 2017 Jul 20;3:17046. doi: 10.1038/nrdp.2017.46. Nat Rev Dis Primers. 2017. PMID: 28726797 Review.
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
Hofste Op Bruinink D, Kuiper R, van Duin M, Cupedo T, van der Velden VHJ, Hoogenboezem R, van der Holt B, Beverloo HB, Valent ET, Vermeulen M, Gay F, Broijl A, Avet-Loiseau H, Munshi NC, Musto P, Moreau P, Zweegman S, van de Donk NWCJ, Sonneveld P. Hofste Op Bruinink D, et al. Among authors: van duin m. J Clin Oncol. 2022 Sep 20;40(27):3132-3150. doi: 10.1200/JCO.21.01217. Epub 2022 Mar 31. J Clin Oncol. 2022. PMID: 35357885 Free PMC article.
128 results